Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Camp4 Therapeutics (CAMP) Equity Average (2023 - 2025)

Camp4 Therapeutics' Equity Average history spans 3 years, with the latest figure at $53.2 million for Q4 2025.

  • For Q4 2025, Equity Average rose 211.0% year-over-year to $53.2 million; the TTM value through Dec 2025 reached $53.2 million, up 211.0%, while the annual FY2025 figure was $55.4 million, 282.96% up from the prior year.
  • Equity Average for Q4 2025 was $53.2 million at Camp4 Therapeutics, up from $49.3 million in the prior quarter.
  • Across five years, Equity Average topped out at $57.4 million in Q1 2025 and bottomed at -$153.0 million in Q3 2024.
  • The 3-year median for Equity Average is -$47.9 million (2024), against an average of -$42.6 million.
  • The largest annual shift saw Equity Average surged 59.27% in 2024 before it skyrocketed 211.0% in 2025.
  • A 3-year view of Equity Average shows it stood at -$117.6 million in 2023, then soared by 59.27% to -$47.9 million in 2024, then surged by 211.0% to $53.2 million in 2025.
  • Per Business Quant, the three most recent readings for CAMP's Equity Average are $53.2 million (Q4 2025), $49.3 million (Q3 2025), and $45.8 million (Q2 2025).